<DOC>
	<DOCNO>NCT00918489</DOCNO>
	<brief_summary>Primary objective study investigate efficacy vorinostat patient suffer select histological type soft tissue sarcoma . Further evaluation relate safety tolerability vorinostat , pharmacokinetics ( course plasma concentration time ) pharmacodynamics ( mode action ) . Only subject advance , metastatic disease include trail .</brief_summary>
	<brief_title>Study Efficacy Tolerability Vorinostat Patients With Advanced , Metastatic Soft Tissue Sarcoma ( STS )</brief_title>
	<detailed_description>The treatment vorinostat administer daily 28 day . This period refer therapy cycle . Two consecutive therapy cycle separate 7-days therapy break . In case good response relevant side effect , treatment vorinostat continue 1 year begin treatment . If relevant side effect intolerability occur , dose and/or schedule administration modify accord pre-defined criterion .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>1 . Patients verify , metastatic soft tissue sarcoma follow histology : undifferentiated highgrade pleomorphic sarcoma/pleomorphic malignant fibrous histiocytoma , undifferentiated pleomorphic sarcoma grand cells/grand cell fibrotic histiocytoma , undifferentiated pleomorphic sarcoma prominent inflammation/inflamed MFH , myxofibrosarcoma , liposarcoma , synovial sarcoma , rhabdomyosarcoma ( pleomorph , alveolar und embryonal ) , leiomyosarcoma , adult fibrosarcoma , angiosarcoma , malignant hemangiopericytoma/ malignant solitaire fibrous tumor , malignant peripheral neurilemma tumor , extraskeletal mesenchymal chondrosarcoma , extraskeletal myxoid chondrosarcoma , undifferentiated sarcoma non specify ( NOS ) type . 2 . Verified relapse disease progression study inclusion , i.e . therapeutic failure first line therapy anthracyclines , 3 . Measurable disease accord RECIST criterion , 4 . Previous systemic therapy advance and/or metastatic disease , 5 . An interval least 4 week since last surgery , chemotherapy radiation , 6 . Age 18 , 7 . Following laboratory finding : ANC ≥ 1.0 x 10³/mm³ , platelet ≥ 100.000/mm³ , hemoglobin ≥ 9 g/dl , creatinin &lt; 1.5 x ULN ( upper limit normal ) , AST ALT &lt; 2.5 x ULN , total bilirubin &lt; 1.5 x ULN , 8 . Life expectancy least 12 week , 9 . Negative pregnancy test , 10 . Consent effective contraception 6 month study completion . 11 . Written informed consent , 12 . Ability understand goal consequence trial . 1 . Proof follow histology : gastrointestinal stromal tumor ( GIST ) , malignant mesothelioma , neuroblastoma , osteosarcoma , Ewing 's sarcoma/PNET , 2 . Concurrent radio chemotherapy , 3 . Participation another interventional trial within 4 week prior inclusion , 4 . Previous therapy another HDACinhibitor ( e.g . depsipeptide , MS275 , LAQ824 , PXD101 und valproic acid ) . Patients , underwent therapy valproic acid treatment seizure , include washout period least 30 day , 5 . Symptomatic brain metastasis , treat radiotherapy . The interval last radiation study inclusion must shorter 30 day , 6 . Previous malignant disease ( except nonmelanoma skin carcinoma situ uterus ) , unless complete remission last therapy least 5 year , 7 . Ejection fraction &lt; 40 % , 8 . Nursing , 9 . Known allergy IMP drug similar chemical structure additives , 10 . Active hepatitis B and/or C HIVinfection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>soft tissue sarcoma</keyword>
	<keyword>metastatic</keyword>
	<keyword>vorinostat</keyword>
</DOC>